<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480086</url>
  </required_header>
  <id_info>
    <org_study_id>M20-248</org_study_id>
    <secondary_id>2020-001226-65</secondary_id>
    <nct_id>NCT04480086</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis</brief_title>
  <official_title>A Phase 1b Study of Mivebresib Alone or in Combination With Ruxolitinib or Navitoclax in Subjects With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body.&#xD;
      MF disturbs the body's normal production of blood cells, causing extensive scarring in the&#xD;
      bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The&#xD;
      purpose of this study is to see how safe and tolerable mivebresib is, when given alone, and&#xD;
      in combination with navitoclax or ruxolitinib, for adult participants with MF.&#xD;
&#xD;
      Mivebresib is an investigational drug being developed for the treatment of MF. The study has&#xD;
      4 segments - A, B, C, and D. In Segment A, the safe dosing regimen of mivebresib is&#xD;
      identified, and then given alone as monotherapy. In Segment B, C, and D, combination&#xD;
      therapies of mivebresib with either ruxolitinib or navitoclax are given. Adult participants&#xD;
      with a diagnosis of MF will be enrolled. Around 130 participants will be enrolled in 60 sites&#xD;
      worldwide.&#xD;
&#xD;
      In Segment A, participants will receive different doses and schedules of oral mivebresib&#xD;
      tablet to identify a safe dosing regimen. Additional participants will be enrolled at the&#xD;
      identified monotherapy dosing regimen. In Segment B, participants will receive oral&#xD;
      ruxolitinib and mivebresib will be given as &quot;add-on&quot; therapy. In Segment C, participants will&#xD;
      receive mivebresib and oral navitoclax. In Segment D, participants will receive mivebresib&#xD;
      and ruxolitinib. Participants will receive treatment until disease progression or the&#xD;
      participants are not able to tolerate the study drugs.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow&#xD;
      tests, checking for side effects, and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up To Approximately 1 year from start of study</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Spleen Volume Reduction of 35% or Greater (SVR35)</measure>
    <time_frame>Up To Week 24</time_frame>
    <description>Reduction in spleen volume is measured by magnetic resonance imaging (MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Mivebresib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of Mivebresib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of Mivebresib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>The amount of time taken to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Concentration vs Time Curve (AUC) of Mivebresib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>AUC of Mivebresib will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) of Mivebresib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Half-life of Mivebresib will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio of Mivebresib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Pharmacokinetic parameters will include accumulation ratio of Mivebresib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of Mivebresib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>CL/F of Mivebresib will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of Mivebresib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Vd/F of mivebresib will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt;= 50% Reduction in Total Symptom Score (TSS)</measure>
    <time_frame>Week 24</time_frame>
    <description>TSS is assessed using the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0. MFSAF v4.0 measures the burden of myelofibrosis-related symptoms. The symptoms are assessed on a 11-point numeric rating scale (NRS) anchored from 0 (absent) to 10 (worst imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Week 24</time_frame>
    <description>ORR is defined as the sum of rates of complete remission (CR) and partial remission (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Navitoclax</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax) Of Navitoclax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of Navitoclax</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>The amount of time taken to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Concentration vs Time Curve (AUC) of Navitoclax</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>AUC of Navitoclax will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax) Of Ruxolitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of Ruxolitinib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>The amount of time taken to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Concentration vs Time Curve (AUC) of Ruxolitinib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>AUC of Ruxolitinib will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Myelofibrosis (MF)</condition>
  <arm_group>
    <arm_group_label>Segment A: Mivebresib Dose Identification and Optimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of mivebresib to identify the safe dosing regimen and schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment A: Mivebresib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified safe dosing regimen of mivebresib as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment B: Ruxolitinib + Mivebresib &quot;Add-on&quot; Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and mivebresib as &quot;add-on&quot; therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment C: Mivebresib + Navitoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have previously been exposed to JAKi, and stopped such therapy, will receive mivebresib and navitoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment D: Mivebresib + Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have never received JAKi will receive mivebresib and ruxolitinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mivebresib</intervention_name>
    <description>Tablet: Oral</description>
    <arm_group_label>Segment A: Mivebresib Dose Identification and Optimization</arm_group_label>
    <arm_group_label>Segment A: Mivebresib Monotherapy</arm_group_label>
    <arm_group_label>Segment B: Ruxolitinib + Mivebresib &quot;Add-on&quot; Therapy</arm_group_label>
    <arm_group_label>Segment C: Mivebresib + Navitoclax</arm_group_label>
    <arm_group_label>Segment D: Mivebresib + Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navitoclax</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Segment C: Mivebresib + Navitoclax</arm_group_label>
    <other_name>ABT-263</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Segment B: Ruxolitinib + Mivebresib &quot;Add-on&quot; Therapy</arm_group_label>
    <arm_group_label>Segment D: Mivebresib + Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory values indicative of adequate bone marrow, renal, and hepatic function&#xD;
             meeting protocol criteria&#xD;
&#xD;
          -  Completion of the Myelofibrosis System Assessment Form (MFSAF) on at least 4 out of&#xD;
             the 7 days prior to Day 1 with at least 2 symptoms with a score &gt;=3 or a total score&#xD;
             of &gt;=10.&#xD;
&#xD;
          -  Documented diagnosis of intermediate or high-risk primary myelofibrosis (PMF),&#xD;
             post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocytopenia&#xD;
             myelofibrosis (PET-MF) as defined by World Health Organization (WHO).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Intermediate - 2, or High-Risk disease as defined by the Dynamic International&#xD;
             Prognostic Scoring System (For Segment A only, Intermediate - 1 with palpable&#xD;
             splenomegaly &gt;=5 centimeters [cm] below costal margin are also eligible).&#xD;
&#xD;
          -  Splenomegaly defined as spleen palpation measurement &gt;= 5 centimeters (cm) below&#xD;
             costal margin or spleen volume &gt;= 450 cubic cms as assessed by Magnetic Resonance&#xD;
             Imaging (MRI) or Computed Tomography (CT) scan (for Segments A and c, baseline spleen&#xD;
             assessment must be obtained &gt; 7 days after discontinuation of most recent&#xD;
             Myelofibrosis (MF) therapy. If possible, this assessment should occur within 10 days&#xD;
             of Cycle 1 Day 1).&#xD;
&#xD;
        Segment-Specific Prior Therapy Criteria:&#xD;
&#xD;
          -  Segment A:&#xD;
&#xD;
             --Prior exposure to one or more Janus Kinase Inhibitors (JAKi), the most recent of&#xD;
             which was discontinued &gt; 28 days prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Segment B:&#xD;
&#xD;
               -  Currently receiving ruxolitinib; AND&#xD;
&#xD;
               -  Willingness to reduce dose (if on a higher dose); and on a stable dose for 14&#xD;
                  days or longer prior to Cycle 1 Day 1; AND&#xD;
&#xD;
               -  At least one of the following criteria (a, b, or c):&#xD;
&#xD;
                    1. &gt;= 24 weeks duration of current ruxolitinib course, with evidence of disease&#xD;
                       that is resistant, refractory, or has lost response to ruxolitinib&#xD;
                       monotherapy;&#xD;
&#xD;
                    2. &lt; 24 weeks duration of current ruxolitinib course with documented disease&#xD;
                       progression as defined by any of the following:&#xD;
&#xD;
                         -  Appearance of new splenomegaly that is palpable to at least 5&#xD;
                            centimeters (cm) below the left costal margin (LCM), in participants&#xD;
                            with no evidence of splenomegaly prior to the initiation of&#xD;
                            ruxolitinib.&#xD;
&#xD;
                              -  100% increase in the palpable distance below the LCM, in&#xD;
                                 participants with measurable spleen distance 5 - 10 cm prior to&#xD;
                                 the initiation of ruxolitinib.&#xD;
&#xD;
                              -  50% increase in the palpable distance below the LCM, in&#xD;
                                 participants with measurable spleen &gt; 10 cm prior to the&#xD;
                                 initiation of ruxolitinib.&#xD;
&#xD;
                         -  A spleen volume increase &gt;= 25% (as assessed by MRI or CT) in&#xD;
                            participants with a spleen volume assessment available prior to the&#xD;
                            initiation of ruxolitinib.&#xD;
&#xD;
                    3. Prior treatment with ruxolitinib for &gt;= 28 days complicated by any of the&#xD;
                       following:&#xD;
&#xD;
                         -  Development of red blood cell transfusion requirement (at least 2&#xD;
                            units/month for 2 months).&#xD;
&#xD;
                         -  Grade &gt;= 3 adverse events of neutropenia and/or anemia while on&#xD;
                            ruxolitinib treatment, with improvement or resolution upon dose&#xD;
                            reduction.&#xD;
&#xD;
          -  Segment C:&#xD;
&#xD;
               -  Prior exposure to one or more JAKi (the most recent of which was discontinued &gt;&#xD;
                  28 days prior to Cycle 1 Day 1), and are intolerant, resistant, refractory or&#xD;
                  lost response to teh JAKi.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Segment-Specific Prior Therapy Criteria:&#xD;
&#xD;
          -  Segment A:&#xD;
&#xD;
             --Prior exposure to one or more Bromodomain and Extra Terminal (BET) inhibitors.&#xD;
&#xD;
          -  Segment B:&#xD;
&#xD;
             --Prior exposure to one or more BET inhibitors.&#xD;
&#xD;
          -  Segment C:&#xD;
&#xD;
             --Prior exposure to one or more BET inhibitors and/or any B-Cell Lymphoma 2 (BCL2)&#xD;
             and/or B-Cell Lymphoma XL (BCLXL) inhibitor, including navitoclax.&#xD;
&#xD;
          -  Segment D:&#xD;
&#xD;
               -  Prior exposure to JAKi and/or any BET inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stony Brook University Hospital /ID# 222653</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health - Cincinnati /ID# 224079</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-2800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Ctr /ID# 225802</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center /ID# 221652</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System /ID# 224234</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108-1532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires /ID# 226946</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1199</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral /ID# 228910</name>
      <address>
        <city>Pilar</city>
        <zip>1629</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital /ID# 224043</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsangbugdo</state>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Health Consortium (Pty) Ltd /ID# 222669</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Alberts Stem Cell Transplant Centre /ID# 222667</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0044</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town /ID# 222666</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 227711</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koç Üniversitesi Hastanesi Translasyonel Tıp Araştırma Merkezi /ID# 227712</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medical Faculty /ID# 227710</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Korea, Republic of</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mivebresib</keyword>
  <keyword>Navitoclax</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>ABT-263</keyword>
  <keyword>Cancer</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>MF</keyword>
  <keyword>ABBV-075</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

